20 million more than American suffer from the osteodistrofia, with half of million American that has a total common replacement each year. A new study to be published in the edition of April 2008 (volume 22, edition No. 4) of the periodical of the research of Phytotherapy it shows Pycnogenol (pic-noj-en-todo), an extract antioxidant of the plant of bark of the French maritime tree of the pine, was shown to reduce all the symptoms of the osteodistrofia for 56 percent. The study efficacy particularly high of Pycnogenol disclosed one to lower common pain for 55 percent. Moreover, the patients had required dramtica medication more little standard of pain (-58 percent), that percent improved the complications extremely gastrointestinal resulting of medication of pain for 63.
“Pycnogenol seemed a natural adjustment for this study,” said the Dr. Gianni Belcaro, an investigator of the linking of the study. “it has some main components that contribute to the clinical picture of the management of the treatment in the osteodistrofia: inflammation that cause a progression in the illness, the alteration of the resistance of tires and the muscular performance - inverting and obstructing the problems vascular it associated with modified mobility. Terica, a treatment with a specifically active composition in all those aspects could highly be efficient, that were because we choose Pycnogenol.”
The study randomized, double-blind, placebo-controlled, arrested in the university of Chieti-PescaraItaly, proved 156 patients with osteodistrofia of the knee (OA). The 100 patients were managed magnesium Pycnogenol or placebo, daily for three months. The symptoms had been evaluated by countings and mobility of the WOMAC index recording its performance walking in one treadmill. The patients had been allowed to continue making examination of its choice of medication of pain had supplied had more recorded them each tablet in a daily one for a delayed evaluation.
To describe and the symptoms of the osteodistrofia of the tax (common pain, rigidity and physical function), WOMAC questionnaires had been evaluated by the investigator and the patient in the beginning and after three months of the treatment. The patients had been trained in a test of treadmill and the performance evaluation was recorded in the total distance that could be covered without pain. The volume of measurement of the foot for the method of the water-displacement was used to inside evaluate edema of ankle/foot in a aleatria sub-group chosen team of the subjects of the two groups of the treatment.
After three months, the countings it left pain significantly to fall for the group of the treatment of Pycnogenol and nenhuns significant effect had been recorded for the group of placebo. The countings for the rigidity had been reduced by 53 percent. The countings for the physical function had been reduced by 57 percent in the group of Pycnogenol and the improvement under placebo was not significant. The global counting of WOMAC very diminished following treatment of Pycnogenol and little in the group of placebo, of 56 percent against. 9,6 percent for Pycnogenol and placebo, respectively. The welfare total of the patients (emotional function) was enhanced significantly with the group of Pycnogenol, for 64 percent and 15 percent for the group of placebo.
The results of tests of the exercise in treadmill had demonstrated to a performance increased after three months of the treatment of Pycnogenol. In the beginning of the study, the patients could only walk a way of 74 yards without pain it feeling and after three months, could walk 216 yards, comparative to the group of placebo that she wrote down 71 yards in the start of the study and 96 yards in the extremity.
Beyond to the results the osteodistrofia, 76 percent of the patients in the group of Pycnogenol and 79 percent in the group of placebo had shown edema visible of the ankle and the foot in inclusion of the study. After the three months, edema only diminished in 79 percent of the patients of Pycnogenol and in a percent in placebo-treat patients.
They had been allowed the patients to use its dosage to regulate of NSAIDS. The use left to fall for 58 percent during the treatment with Pycnogenol and for a percent with placebo. The evaluation of the data demonstrated a gastrointestinal reduction of 64 complications of percent in the group of Pycnogenol against three percent in placebo.
“the results of this study are significant because they demonstrate clearly to the clinical action of Pycnogenol in the OA and the management of the symptoms. The use of Pycnogenol many reduces costs and side effects of agents anti-inflammatory and offers a natural alternative solution to populate to suffer from the OA “said the Dr. Belcaro.
A preceding study in the osteodistrofia that was carried through in the university of Arizona Tucson (published in the research of nutrition) it had discovered that Pycnogenol was efficient to improve the pain and the function of the junction. After three months in the group of Pycnogenol, percent in pain had a reduction of 43, 35 percent in the rigidity, 52 percent in subscales physicists of the function, respectively. The group of placebo all did not show no significant counting during the entire study. The Dr. Belcaro confirms this more in advance a study with a very bigger number of the patients and with a detailed procedure more of the inquiry.
The benefits of Pycnogenol for junctions arthritic are suggested to result predominantly of potency anti-inflammatory of Pycnogenol that was demonstrated in a series of clinical inquiries in the past. It has more studies of the discovery in Pycnogenol and waited osteodistrofia to be published following year allowing the innovative, natural formula development for the common health. Additionally, the research of Horphag, the exclusive deliverer worldwide of Pycnogenol filed for diverse patents for the application of Pycnogenol for COX-1, COX-2 and osteodistrofia of the treatment.
“the new research in the field of the osteodistrofia was a displacement of paradigm for Pycnogenol. We could demonstrate to the impact of Pycnogenol in all the parameters inflammatory and have occurred in supplying the strong clinical evidence of efficacy of Pycnogenol in this field. He is obvious that Pycnogenol will have that to be considered as a innovative ingredient of the choice for the common market of the health, “said the Ferrari winner, CEO of the research of Horphag, exclusive supplier worldwide of Pycnogenol.
The article was adaptou today for Medical Notice of the release of the original press.
On Pycnogenol
Pycnogenol is a natural extract of the plant that it originates from bark of the maritime pine that grows to the long one of the southwestern coast France and is found to contain an original combination of procyanidins, of bioflavonoids and acid the organic ones, that they offer extensive natural benefits of health. The extract was studied extensively per the 35 last years and has more than 220 studies and published articles of revision assuring the security and efficacy as an ingredient. Today, Pycnogenol is available in more than 600 supplements, multi-vitamins and dietary products of the health worldwide. For more information, it visits http://www.pycnogenol.com/.
Natural Health Science Incorporation (NHS), based in Hoboken, Novo-Jersey, is the North American deliverer for French maritime extract of bark of the pine of the type of Pycnogenol (pic-noj-en-todo) on behalf of the research of Horphag. Pycnogenol is a registered mark registada research Ltd. Horphag, Guernsey, and its applications are protected by patents #5,720,956/#6,372,266 and other international patents of United States. NHS has the exclusive right to introduce in the market and to more than vender Pycnogenol in America of the North and benefits of 35 years of the scientific research that assure the security and efficacy of Pycnogenol as a dietary supplement. For more information on the visit of Pycnogenol our Web site in http://www.pycnogenol.com/
Source: Melanie Nimrodi
Group of MWW
Filled under: Uncategorized
Leave a comment or two
